ClearSign Technologies (CLIR) Announces Proposed Stock Offering, Size not Disclosed

ClearSign Technologies Corporation (Nasdaq: CLIR) today announced that it is proposing to sell shares of its common stock in an underwritten public offering. All of the shares in the underwritten public offering are to be sold by ClearSign. ClearSign intends to grant the underwriter a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discount. ClearSign intends to use the net proceeds from the offering for working capital, research and development, marketing and sales, and general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Newbridge Securities Corporation is acting as the sole book-running manager of the offering.

The shares described above are being offered by ClearSign pursuant to a shelf registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. A final prospectus supplement describing the terms of the offering will be filed with the SEC. The offering will be made only by means of the prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, FL 33432, email: [email protected], telephone: (877) 447-9625.

You May Also Be Interested In

• Vincerx Pharma (VINC) Announces Proposed Share and Warrant Offering
• Scilex Holding (SCLX) Prices 15M Share Offering at $1/sh
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results